Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-Label Phase II Study of Response-Guided Bladder Preservation With Trastuzumab Rezetecan Plus Adebrelimab and Concurrent Bladder Radiotherapy in Patients With HER2-Expressing Muscle-Invasive Bladder Cancer

NCT07865611 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT07865611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07865611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-Label Phase II Study of Response-Guided Bladder Preservation With Trastuzumab Rezetecan Plus Adebrelimab and Concurrent Bladder Radiotherapy in Patients With HER2-Expressing Muscle-Invasive Bladder Cancer
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2028
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder cancer (mibc)